Related Experiment Video
Updated: Dec 27, 2025

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Stenting with Acclino (flex) for symptomatic intracranial stenosis as secondary stroke prevention
Lukas Meyer1, Hannes Leischner2, Goetz Thomalla3
1Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany lu.meyer@uke.de.
Insights
Elective intracranial stenting (eICS) using a novel stent and balloon catheter combination showed acceptable safety and efficacy for secondary stroke prevention in patients with symptomatic intracranial stenosis. Further research is needed to optimize antithrombotic strategies and manage in-stent restenosis.
Area of Science:
- Neurology
- Interventional Neuroradiology
- Cardiovascular Medicine
Background:
- Symptomatic intracranial stenosis carries a high risk of stroke recurrence, even with optimal medical management.
- Previous studies on intracranial stenting used older devices, necessitating evaluation of newer technologies.
- Elective intracranial stenting (eICS) is reserved for a select group of high-risk patients.
Purpose of the Study:
- To evaluate the safety and efficacy of a novel device combination for eICS in patients with symptomatic intracranial stenosis.
- To report periprocedural complications and long-term outcomes, including stroke, death, hemorrhage, and stent patency.
Main Methods:
- Retrospective analysis of 76 patients from three high-volume stroke centers treated with Acclino (flex) stent and NeuroSpeed balloon catheter.
- Endpoints included periprocedural stroke or death, intracranial hemorrhage, and stent patency at follow-up.
- Safety assessment encompassed asymptomatic/symptomatic intracranial hemorrhage and adverse events.
Main Results:
- The periprocedural stroke or death rate was 6.5% (2.6% fatal, 3.9% non-fatal).
- Asymptomatic intracranial hemorrhage occurred in 5.2% of patients.
- Follow-up revealed 25% in-stent restenosis, with 11.6% requiring repeat angioplasty.
Conclusions:
- eICS with the Acclino (flex)/NeuroSpeed system appears safe for symptomatic intracranial stenosis, offering an endovascular option for secondary stroke prevention.
- Further studies are required to confirm these findings and optimize management of antithrombotic strategies and in-stent restenosis for long-term patency.
Background And Purpose:
Stroke recurrence is high in patients with symptomatic intracranial stenosis despite best medical treatment. Based on evidence from past studies using previous stent generations, elective intracranial stenting (eICS) is considered in a minority of patients. This study aims to report on experience performing eICS with a novel device combination.
Methods:
We retrospectively reviewed data from three high volume stroke centers and analyzed patients that were treated with eICS for symptomatic intracranial stenosis using the Acclino (flex) stent and the NeuroSpeed balloon catheter (Acandis GmbH, Pforzheim, Germany). Study endpoints were periprocedural rates of stroke regardless of territory or death at discharge and at the time of follow-up after eICS. Safety evaluation included asymptomatic and symptomatic intracranial hemorrhage, serious adverse events related to the intervention, and evaluation of stent patency at the time of follow-up.
Results:
The median age of patients that met the inclusion criteria (n=76) was 69 years. Target vessels were located in the anterior circulation in 55.3% (42/76) of patients. The periprocedural stroke rate was 6.5% (fatal stroke 2.6%; non-fatal stroke 3.9%) at discharge after eICS. Asymptomatic intracranial hemorrhage was observed in 5.2% (4/76) of patients. Follow-up DSA revealed in-stent restenosis of 25% (15/60), and percutaneous transluminal angioplasty was performed again in 11.6% (7/60) of patients.
Conclusion:
Stenting for symptomatic intracranial stenosis with the Acclino (flex)/NeuroSpeed balloon catheter seemed to be safe and reinforces eICS as an endovascular therapy option for secondary stroke prevention. Future studies are warranted to confirm these findings and investigate antithrombotic strategies and in-stent restenosis to minimize periprocedural complications and guarantee long term stent patency.
Related Concept Videos
Mitral Stenosis III: Medical Management
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Peripheral Artery Disease III: Interprofessional Care

